Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis

Background and Objectives To study human leukocyte antigen (HLA) allele associations in anti-leucine–rich glioma-inactivated 1 (LGI1) encephalitis. Methods A multiethnic cohort of 269 patients with anti-LGI1 encephalitis and 1,359 controls was included. Four-digit HLA sequencing and genome wide association single-nucleotide polymorphism typing imputation (0.99 concordance) were used for HLA typing. Significance of primary and secondary associations was tested using χ2, Fisher exact tests, or logistic regression with the control of population stratification covariates when applicable. Results DRB1*07:01 and DQA1*02:01, 2 alleles in strong linkage disequilibrium, were associated with the disease (90% vs 24%, OR = 27.8, p < 10e−50) across ethnicity independent of variation at DRB3 and DQB1, 2 flanking HLA loci. DRB1*07:01 homozygosity was associated with a doubling of risk (OR = 2.1, p = 0.010), suggesting causality. DRB1*07:01 negative subjects were younger (p = 0.003) and more frequently female (p = 0.015). Three patients with malignant thymomas did not carry DRB1*07:01, whereas patients with other tumors had high DRB1*07:01 frequency, suggesting that the presence of tumors other than thymomas may be coincidental and not causal. In both DRB1*07:01 heterozygous individuals and DRB1*07:01 negative subjects, DRB1*04:02 was associated with anti-LGI1 encephalitis, indicating an independent effect of this allele (OR = 6.85, p = 4.57 × 10−6 and OR = 8.93, p = 2.50 × 10−3, respectively). DRB1*04:02 was also independently associated with younger age at onset (β = −6.68, p = 9.78 × 10−3). Major histocompatibility complex peptide-binding predictions using LGI1-derived peptides revealed divergent binding propensities for DRB1*04:02 and DRB1*07:01 alleles, suggesting independent pathogenic mechanisms. Discussion In addition to the established primary DRB1*07:01 association in anti-LGI1 encephalitis, we observe a secondary effect of DRB1*04:02 with lower age at onset. Our study provides evidence for secondary effects within HLA locus that correlate with clinical phenotypes in anti-LGI1 encephalitis.

[1]  N. Sacchi,et al.  High-resolution HLA allele and haplotype frequencies in several unrelated populations determined by next generation sequencing: 17th International HLA and Immunogenetics Workshop joint report. , 2021, Human immunology.

[2]  M. Husain,et al.  Residual Fatigue and Cognitive Deficits in Patients After Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis , 2021, JAMA neurology.

[3]  E. Mignot,et al.  Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis , 2021, Neurology: Neuroimmunology & Neuroinflammation.

[4]  S. Tsuji,et al.  HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data , 2021, Scientific reports.

[5]  K. Kaukinen,et al.  Influence of HLA-DQ2.5 Dose on Clinical Picture of Unrelated Celiac Disease Patients , 2020, Nutrients.

[6]  Peter B. McGarvey,et al.  UniProt: the universal protein knowledgebase in 2021 , 2020, Nucleic Acids Res..

[7]  U. Merle,et al.  Vitamin D Deficiency and Outcome of COVID-19 Patients , 2020, Nutrients.

[8]  M. Elsensohn,et al.  Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[9]  A. Artemiadis,et al.  HLA-DPB1*03 as Risk Allele and HLA-DPB1*04 as Protective Allele for Both Early- and Adult-Onset Multiple Sclerosis in a Hellenic Cohort , 2020, Brain sciences.

[10]  Arjune Sen,et al.  Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms , 2020, Brain : a journal of neurology.

[11]  Dong Zhou,et al.  Novel findings of HLA association with anti-LGI1 encephalitis: HLA-DRB1*03:01 and HLA-DQB1*02:01 , 2020, Journal of Neuroimmunology.

[12]  J. Cerhan,et al.  Genome-wide Association Study Identifies HLA-DPB1 as a Significant Risk Factor for Severe Aplastic Anemia. , 2020, American journal of human genetics.

[13]  D. Schmitz,et al.  Human Cerebrospinal Fluid Monoclonal LGI1 Autoantibodies Increase Neuronal Excitability , 2020, Annals of neurology.

[14]  J. Britton,et al.  Randomized Placebo‐Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy , 2019, Annals of neurology.

[15]  N. Tsuchiya,et al.  Association of HLA-DRB1 genotype with younger age onset and elder age onset rheumatoid arthritis in Japanese populations , 2019, Medicine.

[16]  Morten Nielsen,et al.  Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data , 2019, bioRxiv.

[17]  Liangdan Sun,et al.  Genome‐wide Association Studies of Specific Antinuclear Autoantibody Subphenotypes in Primary Biliary Cholangitis , 2019, Hepatology.

[18]  D. Monos,et al.  Computational assessment of miRNA binding to low and high expression HLA-DPB1 allelic sequences. , 2019, Human immunology.

[19]  C. Geis,et al.  LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory , 2018, Brain : a journal of neurology.

[20]  M. Brown,et al.  HLA class I and II alleles in susceptibility to ankylosing spondylitis , 2018, Annals of the rheumatic diseases.

[21]  J. Knight,et al.  Distinct HLA associations of LGI1 and CASPR2-antibody diseases , 2018, Brain : a journal of neurology.

[22]  W. Lieb,et al.  Genetic predisposition in anti‐LGI1 and anti‐NMDA receptor encephalitis , 2018, Annals of neurology.

[23]  G. Widman,et al.  The importance of early immunotherapy in patients with faciobrachial dystonic seizures , 2017, Brain : a journal of neurology.

[24]  D. Roelen,et al.  Anti‐LGI1 encephalitis is strongly associated with HLA‐DR7 and HLA‐DRB4 , 2017, Annals of neurology.

[25]  K. Chu,et al.  Anti‐LGI1 encephalitis is associated with unique HLA subtypes , 2017, Annals of neurology.

[26]  J. Dalmau,et al.  Anti-LGI1–associated cognitive impairment , 2016, Neurology.

[27]  M. Baulac,et al.  Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. , 2016, Brain : a journal of neurology.

[28]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[29]  A. Desautels,et al.  HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy. , 2015, American journal of human genetics.

[30]  Masahiko Watanabe,et al.  Autoantibodies to Epilepsy-Related LGI1 in Limbic Encephalitis Neutralize LGI1-ADAM22 Interaction and Reduce Synaptic AMPA Receptors , 2013, The Journal of Neuroscience.

[31]  E. Mignot,et al.  Genome Wide Analysis of Narcolepsy in China Implicates Novel Immune Loci and Reveals Changes in Association Prior to Versus After the 2009 H1N1 Influenza Pandemic , 2013, PLoS genetics.

[32]  B S Weir,et al.  HIBAG—HLA genotype imputation with attribute bagging , 2013, The Pharmacogenomics Journal.

[33]  J. Schott,et al.  Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis , 2011, Annals of neurology.

[34]  Sharon R. Browning,et al.  A Polymorphism in the HLA-DPB1 Gene Is Associated with Susceptibility to Multiple Sclerosis , 2010, PloS one.

[35]  A. Vincent,et al.  Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia , 2010, Brain : a journal of neurology.

[36]  H. Adesnik,et al.  Epilepsy-Related Ligand/Receptor Complex LGI1 and ADAM22 Regulate Synaptic Transmission , 2006, Science.

[37]  E. Thorsby,et al.  On the HLA-DQ(alpha 1*0501, beta 1*0201)-associated susceptibility in celiac disease: a possible gene dosage effect of DQB1*0201. , 1993, Tissue antigens.

[38]  Xiuwen Zheng,et al.  Imputation-Based HLA Typing with SNPs in GWAS Studies. , 2018, Methods in molecular biology.

[39]  E. Mignot,et al.  HLA-DQ allele competition in narcolepsy: a comment on Tafti et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. , 2015, Sleep.

[40]  F. Claas,et al.  HLA dosage effect in narcolepsy with cataplexy , 2014, Immunogenetics.

[41]  J. Dalmau,et al.  Thymoma and Autoimmune Encephalitis Clinical Manifestations and Antibodies , 2022 .